Measuring illness insight in patients with alcohol-related cognitive dysfunction using the Q8 questionnaire: A validation study by Walvoort, S.J.W. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/158799
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
© 2016 Walvoort et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2016:12 1609–1615
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1609
O r i g i N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/NDT.S104442
Measuring illness insight in patients with 
alcohol-related cognitive dysfunction using the  
Q8 questionnaire: a validation study
serge JW Walvoort1–3
Paul T van der heijden3,4
roy Pc Kessels1,2,5
Jos iM egger1–3,6
1centre of excellence for Korsakoff 
and alcohol-related cognitive 
Disorders, Vincent van gogh institute 
for Psychiatry, Venray, 2Donders 
institute for Brain, cognition and 
Behaviour, 3Behavioural science 
institute, radboud University, 
Nijmegen, 4reinier van arkel Mental 
health institute, ‘s-hertogenbosch, 
5Department of Medical Psychology, 
radboud University Medical center, 
Nijmegen, 6centre of excellence for 
Neuropsychiatry, Vincent van gogh 
institute for Psychiatry, Venray, the 
Netherlands
Aim: Impaired illness insight may hamper treatment outcome in patients with alcohol-related 
cognitive deficits. In this study, a short questionnaire for the assessment of illness insight (eg, 
the Q8) was investigated in patients with Korsakoff’s syndrome (KS) and in alcohol use disorder 
(AUD) patients with mild neurocognitive deficits.
Methods: First, reliability coefficients were computed and internal structure was investigated. 
Then, comparisons were made between patients with KS and patients with AUD. Furthermore, 
correlations with the Dysexecutive Questionnaire (DEX) were investigated. Finally, Q8 total 
scores were correlated with neuropsychological tests for processing speed, memory, and execu-
tive function.
Results: Internal consistency of the Q8 was acceptable (ie, Cronbach’s α =0.73). The Q8 items 
represent one factor, and scores differ significantly between AUD and KS patients. The Q8 
total score, related to the DEX discrepancy score and scores on neuropsychological tests as 
was hypothesized, indicates that a higher degree of illness insight is associated with a higher 
level of cognitive functioning.
Conclusion: The Q8 is a short, valid, and easy-to-administer questionnaire to reliably assess 
illness insight in patients with moderate-to-severe alcohol-related cognitive dysfunction.
Keywords: illness insight, anosognosia, alcohol use disorder, Korsakoff’s syndrome, cognition, 
neuropsychological assessment
Introduction
Impairments in memory and executive function (EF) are core symptoms of Korsakoff’s 
syndrome (KS), but are also present in patients with alcohol use disorder (AUD).1–6 
Both memory and EF are key features for a successful behavioral change to remain 
abstinent and to restore societal functioning.7–10 One consequence of these cognitive 
dysfunctions in patients with AUD is impaired illness insight.11,12 That is, patients 
typically underestimate the amount of alcohol they have used and the duration of 
their alcohol addiction, and they also misjudge the severe and adverse consequences 
of alcohol addiction on daily life and health functioning.13–15 Impaired illness insight 
can be regarded as a continuum ranging from total denial of the disease to more 
subtle metacognitive awareness deficits.11 Illness insight comprises of awareness of 
illness, the capacity to view symptoms of the disease as pathological, and treatment 
adherence.16
In patients with KS, overestimation of their memory abilities or a failure to rec-
ognize their severity is common due to impaired metamemory.14,17 Compared to the 
information given by the patients themselves, information given by relatives, therapists, 
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and other professional caregivers report that these patients 
show a poor insight into and less awareness of their cogni-
tive deficits.18 Impaired illness insight in alcohol-dependent 
patients might be related to severe retrograde amnesia, 
including deficits in autobiographical memory.19
A wide network of brain structures has been identified as 
being crucial for self-awareness, and includes the prefrontal 
and posterior parietal cortex, the rostral part of the anterior 
cingulate cortex, the insula, and the precuneus.12,20–22 Typi-
cally, these brain areas are susceptible to the negative effects 
of alcohol use.12,23–25 Although this would indicate that func-
tional and structural changes in brain functioning underlie 
impaired illness insight, clinically, lack of illness insight is 
often misinterpreted as a motivational problem or alcoholic 
denial.26–29 Moreover, these alcohol-related cognitive deficits 
can affect the results of self-report questionnaires in such 
a way that it can lead to clinical misinterpretation.13,30–32 
In order to avoid this misinterpretation of alcohol-related 
cognitive deficits, the combined use of self-reported informa-
tion and information reported by informants who know the 
patient very well is essential for adequate diagnosis and in 
particular for the assessment of impaired self-awareness.
Bourgeois et al33 and Bourgeois et al34 developed and 
validated a short questionnaire for measuring illness insight 
in patients with severe psychopathology, the Q8 question-
naire, available in the French language. The Q8 is a short 
and easy-to-administer questionnaire for measuring illness 
insight by means of answering eight questions by the patient 
(Table S1 provides an English translation of the original 
French questions). After the patient has completed the Q8, a 
clinician who knows the patient very well rates each response 
with respect to its adequacy. The total score is the sum of the 
item scores (maximum =8). A score of #2 indicates no illness 
insight; a score of 3–5 indicates poor illness insight; and a 
score of $6 indicates good illness insight. Bourgeois et al34 
examined the Q8 in a mixed-etiology psychiatric sample with 
severe psychopathology (eg, patients with schizophrenia, 
bipolar depression, and addiction). The authors concluded 
that the Q8 has adequate psychometric properties and con-
current validity. However, despite the fact that the Q8 was 
specifically designed for measuring levels of illness insight, 
until now no research has yet been published about its use 
in patients with alcohol-related cognitive deficits.
Therefore, in the present study, we aimed to investigate 
the psychometric properties of the Dutch version of the Q8 in 
patients with severe and mild alcohol-related cognitive deficits. 
First, the internal consistency was investigated. Second, the 
internal structure was studied. We expected all eight items to 
represent one factor. Third, the difference in Q8 total scores 
between KS patients and AUD patients with moderate cog-
nitive deficits was considered. We expected that KS patients 
would have a lower Q8 total score than other AUD patients. 
Next, the Q8 scores were correlated with the Dysexecutive 
Questionnaire (DEX) discrepancy score, a widely used mea-
sure to assess executive problems in daily life as reported 
by the patient and an informant.35 We expected that a lower 
DEX discrepancy score correlated with a lower Q8 total score, 
indicating impaired illness insight. Finally, correlations of the 
Q8 with neuropsychological tests for executive functioning, 
memory, and processing speed were calculated. We hypoth-
esized that impaired illness insight (ie, a lower Q8 total score) 
correlates higher with severe cognitive dysfunction in KS 
patients than in AUD patients with mild cognitive deficits.
Methods
Participants
All data were collected as part of routine outcome monitoring 
of clinical testing and all participants signed a treatment plan. 
The Vincent van Gogh Institutional Review Board did not 
require patient consent be obtained, as the confidential ity of 
participants’ identities was maintained throughout the study 
process. Both the study and study procedure were approved 
by the Vincent van Gogh Institutional Review Board. The 
study was carried out in accordance with the Declaration 
of Helsinki and the Guidelines for Good Clinical Practice 
established by the International Conference on Harmoniza-
tion (CPMP/ICH =135/95). Ninety-seven patients completed 
the Q8 as part of routine clinical assessment (Table 1). All 
were inpatients of the Centre of Excellence for Korsakoff 
and alcohol-related cognitive disorders of the Vincent van 
Gogh Institute for Psychiatry in Venray, the Netherlands. 
Forty-two patients were diagnosed as KS patients fulfilling 
the Diagnostic and Statistical Manual of Mental Disorders, 
5th edition criteria for alcohol-induced major neurocognitive 
disorder36 (including the presence of a persistent memory 
impairment resulting in severe deficits in social functioning, 
the absence of delirium or dementia, a history of alcohol 
abuse disorder, evidence for a history of Wernicke encephal-
opathy, confabulation behavior, and history of malnutrition or 
thiamine deficit) as established by neurological, psychiatric, 
neuroradiological, and neuropsychological examinations.
The AUD group consisted of 55 patients with a 
history of chronic alcohol abuse with mild neurocognitive 
impairments. All AUD control patients met the Diagnostic 
and Statistical Manual of Mental Disorders, 5th edition 
criteria for mild neurocognitive disorder.36 The cognitive 
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impairments were substantiated through neuropsychologi-
cal assessment. None of the AUD patients met the proposed 
clinical criteria for KS or alcohol-related dementia.37 The 
neurocognitive impairments were not a result of another 
medical condition or use of other substances. In both groups, 
the cognitive deficits were substantiated by neuropsycho-
logical assessment.
All patients were abstinent from alcohol for at least 42 days 
at the time of testing. Education level was assessed using seven 
categories in accordance with the Dutch educational system 
(1= less than primary school; 7= university degree38). No sig-
nificant differences were found between the groups regarding 
sex distribution (χ2[1]=0.000, P=0.996). Descriptives of the 
total group (N=97) and differences between the KS (N=42) 
and AUD patients (N=55) are listed in Table 1.
Measures
Questionnaires
The Q8 has been developed and validated in French. For 
this study, the Q8 was translated into Dutch and slightly 
adapted using the original French questions by a clinical 
neuropsychologist with expertise in alcohol-related cogni-
tive disorders (Dr Arie Wester, see “Acknowledgments” 
section).33,34 Consensus was reached in the translation by all 
authors. The resulting research version of the Q8 consists 
of eight questions (Table S1), for example: “Do you experi-
ence limitations in your professional life, your family life, 
or in your social life?” and was administered 5 weeks after 
admission to the clinic. An internal consistency of 0.81 was 
found in a previous study.33,34
The DEX, a subtest of the Behavioural Assessment of the 
Dysexecutive Syndrome35 was administered. There are two 
versions: a patient rating scale (DEX-S) and a rating scale 
for informants (DEX-I; eg, relatives, friends, or professional 
caregivers) who know the patient very well in relation to 
the daily activities/functioning. Both versions are 20-item 
scales in which each item is rated 0= never, 1= occasionally, 
2= sometimes, 3= fairly often, or 4= very often. The DEX 
incorporates cognitive, affective, and behavioral aspects of 
the dysexecutive syndrome. An example of such a question is 
“I find it difficult to keep my mind on something, and am eas-
ily distracted.” Both the patient and his/her primary profes-
sional caregiver from our department completed the DEX. In 
order to investigate the dissociation between self-report and 
behavior, which is commonly seen in addiction,12 discrepancy 
scores for the DEX (DEX-D) were calculated by subtracting 
the informant scores from the self-ratings.11,35 A negative 
discrepancy score indicates higher ratings by the patient 
than by the caregiver, suggestive of illness insight, whereas 
a positive discrepancy score points at a lower rating by the 
caregiver than by the patient and a lack of illness insight. 
Validity of DEX-D scores for detecting poor insight has been 
established previously. David et al,11 for instance, found that 
DEX-D was highly discrepant in patients with Alzheimer 
and patients with brain injury and should be regarded as a 
measure of awareness of dysexecutive problems.
Table 1 Descriptives of the total group (N=97) and differences between Ks (N=42) and aUD patients (N=55)
Total (n=97) KS (n=42) AUD (n=55) ta U P-value Cohen’s d
education (mode and range) 4 (2–7) 4 (2–6) 4 (2–7) 1,137 0.89
alcohol use in years (range) 2–55 2–48 2–55
abstinence in days (range) 42–693 42–693 42–186 1.14 0.26
Mean SD Mean SD Mean SD
age (years) 55.84 8.66 57.36 8.77 54.67 8.47 1.52 0.13
cognitive measures
NarT 92.43 15.10 89.67 14.64 94.55 15.55 –1.59 0.12
Psi* 81.37 15.09 75.2 13.85 86.06 14.39 –3.70 0.00 –0.77
cVlT delayed free recall 5.79 4.72 2.4 3.76 8.38 3.61 -7.94 0.00 -1.62
MseT 2.42 1.27 1.76 1.10 2.93 1.15 -5.03 0.00 -1.04
Questionnaires
DeX-s 21.63 11.08 19.60 11.13 23.18 10.88 -1.59 0.11 -0.33
DeX-i 23.21 12.95 28.40 12.01 19.24 12.31 3.67 0.00 0.75
DeX-D -1.58 16.39 -8.81 15.97 3.95 14.57 3.67 0.00 -0.83
Q8 3.34 2.15 2.48 2.17 4.00 1.90 -3.69 0.00 -0.75
Notes: Values in bold indicate P,0.05. education level was assessed using seven categories in accordance with the Dutch educational system (1= less than primary school; 
7= university degree). NarT, National adult reading Test (standard score);54 *Psi (standard score) of the Wais-iii. cVlT, california Verbal learning Test (raw score); 
MSET, modified six elements test (standard score); DEX-S, DEX-self (raw score); DEX-I, DEX-informant (raw score); DEX-D, discrepancy score of DEX-self (raw score) 
minus DeX-informant (raw score). aindependent samples t-tests. Q8 total score maximum =8.
Abbreviations: aUD, alcohol use disorder; Ks, Korsakoff syndrome; Psi, Processing speed index; sD, standard deviation; Wais-iii: Wechsler adult intelligence scale – 
Third edition.
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Neuropsychological measures
The Modified Six Elements Test (MSET) of the Behav-
ioural Assessment of the Dysexecutive Syndrome35,39 was 
used as a cognitive measure of daily EF and discriminates 
at a clinically significant level between KS and non-KS 
patients.1,40
The delayed free recall raw score of the Dutch version 
of the California Verbal Learning Test (CVLT41) was used 
in the analysis. The CVLT is a word-list learning test that 
has proven to be sensitive in detecting memory impairment 
in chronic alcoholic patients (Walvoort et al, unpublished 
data, 2016).42
Finally, the Processing Speed Index (PSI) of the Wechsler 
Adult Intelligence Scale – Third Edition (WAIS-III43) was 
used, which consists of the subtests Digit Symbol Coding 
and Symbol Search. The PSI has proven to be sensitive in 
detecting impairment in processing speed (Walvoort et al, 
unpublished data, 2016).
Procedure and analysis
Informed consent was obtained from all participants. The 
assessment of the DEX questionnaires and the neuropsy-
chological tests were administered after patients had been 
abstinent from alcohol or other nonmedical drugs for at least 
6 weeks.44 The neuropsychological tests were assessed by an 
experienced psychologist. In this study, the Q8 questionnaire 
was evaluated by an experienced clinical neuropsychologist 
who knows the patient well, 2 weeks prior to neuropsycho-
logical assessment. Reliability of the Q8 was measured by 
computing Cronbach’s α and split-half reliability. Internal 
structure of the Q8 was investigated by principal component 
analysis with varimax rotation. Parallel analysis was per-
formed to determine the number of components that should 
be extracted.45,46
Independent t-tests were performed to measure differ-
ences between KS patients and AUD patients (Table 1). 
Pearson’s correlations coefficients were computed between 
the Q8, the DEX-S, DEX-I, DEX-D score, and the neurop-
sychological measures (MSET, CVLT, and PSI) for both 
groups pooled together.
Results
Cronbach’s α for the Q8 questionnaire was found to be 0.73, 
and Spearman–Brown coefficient was 0.70, which are 
acceptable.47 Principal component analysis on the items in the 
total sample revealed one component accounting for 35% of 
the variance. Principal component analysis was repeated in 
both subsamples to investigate whether the factor structure 
was robust in both subsamples. In both subsamples, one 
factor appeared with somewhat higher loadings in the KS 
subsample (M =0.63) than in the AUD subsample (M =0.47). 
The coefficient of congruence, used to compare the factors 
in both subsamples, was 0.89. As a rule of thumb, Harman48 
proposed that factors are congruent if the coefficient of 
congruence is equal to or greater than 0.94.
As Table 1 indicates, the KS group demonstrated signifi-
cantly lower scores on the Q8 questionnaire than the AUD 
controls. On the Q8, 64% of the KS patients scored ,2 versus 
23% of the AUD controls. Table 2 demonstrates significant 
correlations between the Q8 and the DEX, CVLT recall, 
MSE, and PSI. Correlations of 0.10 are considered small, 
and correlations of 0.30 can be considered medium.49 The 
positive correlations between Q8 and the DEX-S indicate that 
a higher level of illness insight is associated with a higher 
level of self-reported complaints on the DEX-S. Significant 
negative correlations between the Q8 and DEX-I were found, 
indicating that lower scores on the Q8 are associated with 
higher levels of observed dysexecutive problems by the 
informant. Moreover, the DEX-D score showed a positive 
correlation with the Q8, indicating that lower DEX-D scores 
(more symptoms observed by the professional caregiver than 
by the patient) are related with lower scores on the Q8. Posi-
tive correlations between the neuropsychological measures 
(MSET, CVLT, and PSI) and the Q8 were found, revealing 
that better cognitive performance is associated with a higher 
level of illness insight.
Discussion
This study is the first in using the Q8 questionnaire in 
patients with severe and moderate alcohol-related cognitive 
dysfunction for assessing illness insight. Internal consistency 
Table 2 Pearson’s correlations between the Q8, the DeX, the cVlT, the MseT, and Psi
DEX total score Neuropsychological measures
Self Informant Discrepancy CVLT delayed free recall MSET PSI
Q8 0.26* -0.30** 0.41** 0.28** 0.35** 0.26*
Notes: *P,0.05; **P,0.01. Discrepancy = DeX-self score minus DeX-informant score. Q8 total score maximum =8.
Abbreviations: DEX, Dysexecutive Questionnaire; CVLT, California Verbal Learning Test; MSET, modified six elements test; PSI, Processing Speed Index.
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split-half reliability and factor analysis proved that the Q8 
has acceptable psychometric characteristics to assess (lack 
of) illness insight in patients with moderate-to-severe AUD. 
The Q8 scores of KS patients differ from that of AUD 
patients with less severe cognitive impairments, and the Q8 
demonstrates medium correlations with the DEX-D, con-
tributing to the concurrent validity of the Q8. These findings 
demonstrate the concurrent validity of the Q8 total score. 
Finally, as expected, better illness insight, as measured with 
the Q8, correlated with a better performance on measures of 
EF (the MSET), memory (CVLT delayed free recall), and 
processing speed (PSI).
Because the Q8 incorporates self-reported thoughts and 
beliefs of the patient as well as an evaluation by a caregiver 
who knows the patient very well, it has clinical potential as a 
valid tool for assessing illness insight in patients with severe 
psychopathology. Since it consists of eight items, it has a 
shorter administration time than the DEX-D. In addition, 
the Q8 measures illness insight in a more direct manner than 
the DEX-D. The DEX-D, being a measure of awareness in 
dysexecutive symptoms, is a more indirect way of measuring 
illness insight by comparing the “self” and “other” ratings.11 
It should be noted that it is not always easy to gather informa-
tion of relevant others, because the social network of AUD 
patients is often limited.
Another limitation of the Q8 is that data on test–retest 
reliability are not available from the studies of Bourgeois 
et al33,34 or from the present study. Future research should 
address this and could also examine the use of the Q8 
in addicted patients without cognitive dysfunction, as 
the addiction itself also affects illness insight and self-
awareness.18,20,50,51 Also, it would be interesting to evaluate 
the course of illness insight by assessing the Q8 on several 
occasions during abstinence. Kim et al,52 for instance, exam-
ined 117 male alcoholic patients who were abstinent for up 
to 1 year after treatment using a self-report questionnaire 
and found that insight might improve during the course of 
abstinence. Alternatively, one could argue that this improved 
insight may be due to improved cognitive function, in line 
with findings that cognitive function in alcoholic patients 
recovers to some extent during abstinence.44,53
Conclusion
The results of this study confirm that the Q8 questionnaire is 
a reliable and valid measure that provides a significant con-
tribution to the assessment of illness insight in patients with 
moderate and severe alcohol-related cognitive dysfunction. 
It should be stressed that the assessment of illness insight 
should always be performed by using different sources of 
information (eg, neuropsychological measures, self-report 
questionnaires, and information from professional caregiv-
ers) to further optimize clinical decision making and treat-
ment selection.
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Table S1 english version of the Q8
Q8 questions Score
1. Why are you here?
__________________________________________________
2. Do you feel that you are ill?
Yes/NO
3. Which disease or disorder do you have?
__________________________________________________
4. What is the cause of this?
__________________________________________________
5. Do you suffer psychologically or do you experience feelings of guilt?
Yes/NO
6. Do you experience limitations in your professional life, your family life, or in your social life?
Yes/NO
7. how can we help you?
__________________________________________________
8. Do you think you can be treated?
Yes/NO
___________(0/1)
___________(0/1)
___________(0/1)
___________(0/1)
___________(0/1)
___________(0/1)
___________(0/1)
___________(0/1)
Q8 total score ___________(0/8)
Notes: adapted and translated from Bourgeois Ml, Koleck M, Jais e. Validation de l’échelle d’insight Q8 et évaluation de la conscience de la maladie chez 121 patients 
hospitalisés en psychiatrie [Validation of the insight Q8 scale and evaluation of the awareness disorder in 121 psychiatric inpatients]. Ann Med Psychol. 2002;160:512–517. 
French. Copyright © 2002 Éditions scientifiques et médicales Elsevier SAS. All rights reserved. Reproduced with permission.1
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